UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2021

 

or

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________ to ________

 

Commission File Number: 333-169397

 

Tengjun Biotechnology Corp.

(Exact name of small business issuer as specified in its charter)

 

Nevada   27-3042462
(State or other jurisdiction of incorporation)   (I.R.S. Employer Identification Number)

 

527 Siltstone Place,

Cary, NC 27519

(Address of principal executive offices and zip code)

 

(919) 869-0279

(Registrant’s telephone number, including area code)

 

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. YES ☒ NO ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “Non-accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☒
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☒ NO ☐

 

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date.

Class   Outstanding April 16, 2020
Common Stock, $0.001 par value per share   45,783,459 shares

 

 

 

 

 

Tengjun Biotechnology Corp.

 

FORM 10-Q

 

March 31, 2021

 

TABLE OF CONTENTS

 

    Page No.
PART I. - FINANCIAL INFORMATION
     
Item 1.

Financial Statements 

1

 

Condensed Balance Sheets as of March 31, 2021 (Unaudited) and December 31, 2020 

1
 

Unaudited Condensed Statements of Operations for the Three Months Ended March 31, 2021 and 2020 

2
 

Unaudited Condensed Statements of Changes in Stockholders’ Deficit for the Three Months Ended March 31, 2021 and 2020 

3
 

Unaudited Condensed Statements of Cash Flows for the Three Months Ended March 31, 2021 and 2020 

4
  Notes to Unaudited Condensed Financial Statements 5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 9
Item 3. Quantitative and Qualitative Disclosures About Market Risk 11
Item 4. Controls and Procedures 11
     
PART II - OTHER INFORMATION
     
Item 1. Legal Proceedings 12
Item 1A. Risk Factors 12
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 12
Item 3. Defaults upon Senior Securities 12
Item 4. Mine Safety Disclosures 12
Item 5. Other Information 12
Item 6. Exhibits 12
Signatures 13

 

i

 

 

PART 1 - FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

TENGJUN BIOTECHNOLOGY CORP.
CONDENSED BALANCE SHEETS

 

    As of  
    March 31,     December 31,  
    2021     2020  
    (Unaudited)        
ASSETS            
CURRENT ASSETS:            
Cash and cash equivalents   $ 4,052     $ 5,942  
Prepaid expenses     15,135       4,298  
                 
TOTAL CURRENT ASSETS     19,187       10,240  
                 
TOTAL ASSETS   $ 19,187     $ 10,240  
                 
LIABILITIES AND STOCKHOLDERS’ DEFICIT                
                 
CURRENT LIABILITIES:                
Accounts payable and accrued liabilities   $ 11,586     $ 11,636  
Related party loans     301,433       281,107  
                 
TOTAL CURRENT LIABILITIES     313,019       292,743  
                 
STOCKHOLDERS’ DEFICIT:                
Preferred stock ($.001 par value; 5,000,000 shares authorized;0 shares issued and outstanding)     -       -  
Common stock ($.001 par value; 70,000,000 shares authorized;45,783,459 shares issued and outstanding at March 31, 2021 and December 31, 2020)     45,783       45,783  
Additional paid-in capital     254,929       249,454  
Accumulated deficit     (594,544 )     (577,740 )
                 
TOTAL STOCKHOLDERS’ DEFICIT     (293,832 )     (282,503 )
                 
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT   $ 19,187     $ 10,240  

 

The accompanying notes to the unaudited condensed financial statements are an integral part of these statements.

 

1

 

 

TENGJUN BIOTECHNOLOGY CORP.
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS

             
    For the Three Months Ended
March 31, 		 
    2021     2020  
             
Revenues   $ -     $ -  
                 
Operating Expenses:                
Accounting fees     6,500       6,300  
Other general and administrative     4,829       5,051  
                 
Total Operating Expenses     11,329       11,351  
                 
Loss from Operations     (11,329 )     (11,351 )
                 
Other Expense:                
Interest expense - related party     (5,475 )     (5,439 )
                 
Total Other Expense     (5,475 )     (5,439 )
                 
Net Loss   $ (16,804 )   $ (16,790 )
                 
Net loss per common share, basic and diluted   $ (0.00 )   $ (0.00 )
                 
Weighted average number of common shares outstanding:                
Basic and diluted     45,783,459       43,198,109  

 

The accompanying notes to the unaudited condensed financial statements are an integral part of these statements.

 

2

 

 

TENGJUN BIOTECHNOLOGY CORP.
UNAUDITED CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
FOR THE THREE MONTHS ENDED MARCH 31, 2021

                               
                Additional           Total  
    Common Stock     Paid-in     Accumulated     Stockholders’  
    Shares     Amount     Capital     Deficit     Deficit  
                               
Balance at December 31, 2020     45,783,459     $ 45,783     $ 249,454     $ (577,740 )   $ (282,503 )
                                         
Imputed interest     -       -       5,475       -       5,475  
                                         
Net loss for the three months ended March 31, 2021     -       -       -       (16,804 )     (16,804 )
                                         
Balance at March 31, 2021     45,783,459     $ 45,783     $ 254,929     $ (594,544 )   $ (293,832 )

 

TENGJUN BIOTECHNOLOGY CORP.
UNAUDITED CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT
FOR THE THREE MONTHS ENDED MARCH 31, 2020

 

                Additional           Total  
    Common Stock     Paid-in     Accumulated     Stockholders’  
    Shares     Amount     Capital     Deficit     Deficit  
                               
Balance at December 31, 2019     43,136,540     $ 43,137     $ 201,095     $ (523,872 )   $ (279,640 )
                                         
Common stock sold for cash     80,040       80       2,325       -       2,405  
                                         
Imputed interest     -       -       5,439       -       5,439  
                                         
Net loss for the three months ended March 31, 2020     -       -       -       (16,790 )     (16,790 )
                                         
Balance at March 31, 2020     43,216,580     $ 43,217     $ 208,859     $ (540,662 )   $ (288,586 )

 

The accompanying notes to the unaudited condensed financial statements are an integral part of these statements.

 

3

 

 

TENGJUN BIOTECHNOLOGY CORP.
UNAUDITED CONDENSED STATEMENTS OF CASH FLOWS

 

    For the Three Months Ended
March 31, 		 
    2021     2020  
             
CASH FLOWS FROM OPERATING ACTIVITIES:            
Net loss   $ (16,804 )   $ (16,790 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Imputed interest on related party loans     5,475       5,439  
Changes in operating assets and liabilities:                
Increase in prepaid expenses     (10,837 )     (8,838 )
Decrease in accounts payable and accrued liabilities     (50 )     (25 )
                 
NET CASH USED IN OPERATING ACTIVITIES     (22,216 )     (20,214 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES:                
Proceeds received from related party loans     23,012       20,214  
Proceeds from sale of common stock     -       2,405  
Repayment made for related party loans     (2,686 )     (2,405 )
                 
NET CASH PROVIDED BY FINANCING ACTIVITIES     20,326       20,214  
                 
NET DECREASE IN CASH     (1,890 )     -  
                 
Cash, beginning of period     5,942       -  
                 
Cash, end of period   $ 4,052     $ -  
                 
SUPPLEMENTAL DISCLOSURES:                
Interest paid   $ -     $ -  
Income taxes paid   $ -     $ -  

 

The accompanying notes to the unaudited condensed financial statements are an integral part of these statements.

 

4

 

 

TENGJUN BIOTECHNOLOGY CORP.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

 

NOTE 1 - Organization

 

China Herb Group Holdings Corporation (the “Company”) was incorporated under the name “Island Radio, Inc” under the laws of the State of Nevada on June 28, 2010. On December 9, 2019, the Company changed its corporate name to Tengjun Biotechnology Corp. 

 

On June 27, 2012, Eric R. Boyer and Nina Edstrom (collectively, the “Sellers”), who were then the major shareholders of the Company, entered into a Share Purchase Agreement with Chin Yung Kong, Qiuping Lu and Fumin Feng (collectively, the “Purchasers”), pursuant to which the Sellers sold to the Purchasers an aggregate 4,000,000 shares of the common stock of the Company, which represented approximately 93% of the then total issued and outstanding stock of the Company, for a total purchase price of $159,970 (the “Change in Control”). As result of this share purchase transaction, Chin Yung Kong, Qiuping Lu and Fumin Feng became the controlling shareholders of the Company.

 

The Company’s original business plan was to become a commercial FM radio broadcaster. Subsequently, following the Change in Control, the Company changed its business plan and intended to become a medical and spa company with a focus on Asia. However, after consultation with its professional and business advisors in the United States and the People’s Republic of China, the Company’s management decided during the third quarter of 2014 that this would no longer be its plan of operations. The Company’s plan of operations is to evaluate various industries, geographic and market opportunities. This may take the form of acquiring a business, being acquired by an existing business or developing a business organically. Any such efforts may require significant capital, which the Company currently lacks. There is no assurance that any such opportunity will become available. There is also no assurance that, if any opportunity becomes available, the Company will have the financial and other resources available to take advantage of such opportunity, since the Company has extremely limited liquidity. Through March 31, 2021, the Company has no revenues or operation.

  

NOTE 2 - Summary of Significant Accounting Policies

 

Unaudited Interim Financial Information

 

The accompanying balance sheets as of March 31, 2021, statements of operations for the three months ended March 31, 2021 and 2020, statements of changes in stockholders’ deficit for the three months ended March 31, 2021 and 2020, and the statements of cash flows for the three months ended March 31, 2021 and 2020, are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles accepted in the United States of America (“U.S. GAAP”). In the opinion of the Company’s management, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and included all adjustments necessary for the fair presentation of the Company’s statement of financial position at March 31, 2021 and its results of operations and its cash flows for the period ended March 31, 2021. The results for the period ended March 31, 2021 are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2021.  

 

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with U.S. GAAP for financial information and in accordance with Regulation S-X promulgated by the Securities and Exchange Commission (the “SEC”). They reflect all adjustments which are, in the opinion of the Company’s management, necessary for a fair presentation of the financial position as of March 31, 2021 and operating results for the three months ended March 31, 2021 and 2020. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K, for the year ended December 31, 2020, filed with the SEC on February 17, 2021.

 

Use of Estimates

 

The accompanying financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America. Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements for a period necessarily involves the use of estimates which have been made using careful judgment. Actual results may vary from these estimates.

 

5

 

 

Fair Value of Financial Instruments

 

ASC 820, “Fair Value Measurements” and ASC 825, Financial Instruments, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. It establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. It prioritizes the inputs into three levels that may be used to measure fair value:

 

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

 

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

 

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

 

As of March 31, 2021 and December 31, 2020, the Company believes that the recorded values of all of its financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

  

Description     Level 1       Level 2       Level 3       Total Realized Loss  
March 31, 2021     -       -       -       -  
December 31, 2020     -       -       -       -  

 

ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

 

Cash and Cash Equivalents

 

For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents. As of March 31, 2021 and December 31, 2020, the Company had no cash equivalents.

 

Prepaid Expenses

 

Prepaid expenses relate to cash paid in advance for annual listing fee and business license. These amounts are recognized as expense over the related listing and service periods. At March 31, 2021 and December 31, 2020, prepaid expenses amounted $15,135 and $4,298, respectively.

 

6

 

 

Income Taxes

 

Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending upon the classification of the assets or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

 

The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10 “Uncertainty in Income Taxes” (ASC 740-10). Certain recognition thresholds must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax positions that meet a “more-likely-than-not” threshold. As of March 31, 2021 and December 31, 2020, the Company does not believe it has any uncertain tax positions that would require either recognition or disclosure in the accompanying financial statements.

 

Loss per Share Calculation

 

Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per shares is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. During the three months ended March 31, 2021 and 2020, the Company had no dilutive financial instruments issued or outstanding. 

  

Recent Accounting Pronouncements

 

Accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures. 

 

NOTE 3 - Going Concern

 

The Company has minimal operations, and as such has devoted most of its efforts since its inception to developing its business plan, issuing common stock, attempting to raise capital, establishing its accounting systems and other administrative functions.

 

As of March 31, 2021, the Company had $4,052 in cash and has been funding its working capital needs from loans from related parties. The Company is seeking sources of funding. Without limiting its available options, future equity financings will most likely be through the sale of additional shares of its common stock. It is possible that the Company could also offer warrants, options and/or rights in conjunction with any future issuances of its common stock. However, the Company can give no assurance that financing will be available to it, and if available, in amounts or on terms acceptable to the Company.

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established a source of revenues sufficient to cover its operating costs, and as such, has incurred an operating loss since its inception. Further, as of March 31, 2021, the Company had a working capital deficit, accumulated deficit and stockholders’ deficit of $293,832, $594,544 and $293,832, respectively. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments or classifications that may result from the possible inability of the Company to continue as a going concern.

 

7

 

 

NOTE 4 - Related Party Transactions

 

Related Party Loans

 

Qiuping Lu, President, CEO, director and shareholder of the Company, advanced funds to the Company for working capital purposes. These working capital advances are payable on demand. As of March 31, 2021 and December 31, 2020, these working capital advances amounted to $301,433 and $281,107, respectively, are reflected as related party loans on the accompanying balance sheets.

 

During the three months ended March 31, 2021 and 2020, in connection with these related party loans, the Company imputed interest of $5,475 and $5,439, respectively, and recorded interest expense and an increase in additional paid-in capital.

 

Office Space from Related Party

 

The Company uses office space of a related party, free of rent, which is considered immaterial.

 

NOTE 5 – Stockholders’ Deficit

 

Preferred Stock

 

The total number of preferred shares authorized that may be issued by the Company is 5,000,000 shares with a par value of $0.001 per share.

 

As of March 31, 2021 and December 31, 2020, the Company had no shares of its preferred stock issued and outstanding.

 

Common Stock

 

The total number of common shares authorized that may be issued by the Company is 70,000,000 shares with a par value of $0.001 per share.

 

As of March 31, 2021 and December 31, 2020, the Company had 45,783,459 shares of its common stock issued and outstanding.

 

NOTE 6 – Commitments and Contingencies

 

At March 31, 2021, there were no legal proceedings against the Company.

 

NOTE 7 – Subsequent Events

 

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined there are no additional events required to be disclosed.

 

8

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

We have limited operations and are not currently generating any revenues from our business operations. Our independent registered public accounting firm has issued a going concern opinion for the year ended December 31, 2020. This means that our auditors believe there is substantial doubt that we can continue as an on-going business for the next 12 months. We do not anticipate generating significant revenues until we acquire a business, are acquired by an existing business or develop a business organically. Accordingly, we must raise additional cash from sources other than operations.

 

We presently are exploring other such sources of funding, including raising funds through a public offering, a private placement of securities, debt or a combination of the foregoing. If we are unable to raise additional capital, we will either have to suspend operations until we do raise the cash or cease operations entirely.

 

The following discussion should be read in conjunction with our Financial Statements and the notes thereto and the other information included in this Annual Report as filed with the SEC on Form 10-K.

 

Overview

 

Our original business plan was to become a commercial FM radio broadcaster. Subsequently, following a change in control, we changed our business plan and intended to become a medical and spa company with a focus on Asia. However, after consultation with our professional and business advisors in the United States and the People’s Republic of China, management decided during the third quarter of 2014 that this would no longer be our plan of operations. Our plan of operations is to evaluate various industries, and geographic and market opportunities. This may take the form of acquiring a business, being acquired by an existing business or developing a business organically. Any such efforts may require significant capital, which we currently lack. There is no assurance that any such opportunity will become available. There is also no assurance that, if any opportunity becomes available, we will have the financial and other resources available to take advantage of such opportunity, since we have extremely limited liquidity. Through March 31, 2021, we had no revenues or operations. 

 

Results of Operations

 

The Three Months Ended March 31, 2021 Versus Three Months Ended March 31, 2020

 

Revenues. As of March 31, 2021, we had not generated any revenues.

 

Operating Expenses. For the three months ended March 31, 2021, total operating expenses amounted to $11,329 as compared to $11,351 for the three months ended March 31, 2020, a decrease of $22 or 0.2%. Since inception, our operating expenses primarily consisted of fees and expenses related to complying with our ongoing SEC reporting requirements, which have consisted of accounting fees, transfer agent fees, and filing fees etc.

 

Other expenses. During the three months ended March 31, 2021 and 2020, we recorded $5,475 and $5,439, respectively, in imputed interest expenses related to advances outstanding to related party. These imputed interests were recorded in our financial statements under additional paid-in capital. 

 

Net Loss. During the three months ended March 31, 2021 and 2020, we had a net loss of $16,804 and $16,790, respectively.

 

Liquidity and Capital Resources

 

As of March 31, 2021, we had $4,052 in cash, while, we had liabilities of $313,019, and had a working capital deficit of $293,832. We expect to incur continued losses during 2021, possibly even longer.

 

For the three months ended March 31, 2021 and 2020, net cash used in operating activities amounted to $22,216 and $20,214, respectively. We expect to require working capital of approximately $50,000 over the next 12 months to meet our financial obligations.

 

For the three months ended March 31, 2021 and 2020, net cash provided by financing activities amounted to $20,326 and $20,214, respectively. For the three months ended March 31, 2021, we received proceeds from loans from officer of $23,012, offset by repayment made for loans from officer of $2,686.  For the three months ended March 31, 2020, we received proceeds from loans from officer of $20,214, received proceeds from sale of common stock of $2,405, and made repayment for loans from officer of $2,405. 

 

9

 

 

We have not generated any revenues from operations to date. It is not likely that we will generate any revenue until at least a business combination has been consummated. Even following a business combination, there is no guarantee that any revenues will be generated or that any revenues will be sufficient to meet our expenses. We may consider a business combination with a target company which itself has recently commenced operations, is a developing company in need of additional funds for expansion into new products or markets, is seeking to develop one or more new products or services, or is an established business which may be experiencing financial or operating difficulties and is in need of additional capital.

 

The foregoing considerations raise substantial doubt about our ability to continue as a going concern.  We are currently planning on devoting the vast majority of our efforts to identifying, investigating and conducting due diligence on target companies; and negotiating, structuring, documenting and consummating a business combination. Our long-term ability to continue as a going concern is dependent upon our ability to develop additional sources of capital, complete a business combination and, thereafter, achieve profitable operations.

 

We believe that we will be able to meet these costs through cash on hand and additional amounts, as may be necessary, to be loaned by or invested in us by our stockholders, management and/or others. Currently, however, our ability to continue as a going concern is dependent upon our ability to generate future profitable operations and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due.  Our ability to continue as a going concern is also dependent on our ability to find a suitable target company and enter into a business combination.  Management’s plan includes obtaining additional funds through a combination of sales of our equity securities before, contemporaneously with, or following, the consummation of a business combination; and borrowings, although we do not believe that we will be eligible to borrow funds from a bank until at least a business combination is consummated.  However, there is no assurance that any additional funding will be available on terms that are favorable to us or at all.

 

We currently rely on loans from our sole director and officer, Qiuping Lu. There is no guarantee that Ms. Lu will continue to lend us funds to meet our expenses in the future. Currently, we do not have any other arrangements for financing.  We have no assurance that future financing will be available to us on acceptable terms, or at all. If financing is not available to us on satisfactory terms or at all, we may be unable to develop operations or meet our expenses.  Additionally, any equity financing in which we might engage would result in dilution to our existing shareholders.

 

During the three months ended March 31, 2021 and 2020, Ms. Lu, the sole director and officer of us, advanced an aggregate $23,012 and $20,214, respectively, to us to pay some of our expenses and for working capital purposes, and we repaid $2,686 and $2,405, respectively, to Ms. Lu. These advances in the aggregate amounts of $301,433 and $281,107, respectively, at March 31, 2021 and December 31, 2020, are payable on demand and are reflected as related party loans on the accompanying balance sheets.

 

Imputed interest of $5,475 and $5,439 was recorded for the three months ended March 31, 2021 and 2020, respectively, and the imputed interest was recorded as interest expense and an increase in additional paid-in capital, respectively.

 

Going Concern Consideration

 

Our independent registered public accounting firm has issued a going concern opinion in their audit report dated February 17, 2021, which can be found in our Annual Report on Form 10-K filed with the SEC on February 17, 2021. This means that our auditors believe there is substantial doubt that we can continue as an on-going business for the next 12 months. Our financial statements found within this Quarterly Report on Form 10-Q and the aforementioned Annual Report on Form 10-K contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors.

 

Contractual Obligations

  

As of March 31, 2021, we had no contractual obligations.

 

Off –Balance Sheet Operations

 

As of March 31, 2021, we had no off-balance sheet activities or operations.

 

Critical Accounting Policies

 

Please refer to Note 2 - Summary of Significant Accounting Policies of our financial statements accompanying this report.

 

Recently Issued Accounting Pronouncement

 

For details of applicable new accounting standards, please, refer to Recent Accounting Pronouncements in Note 2 of our financial statements accompanying this report.

 

10

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures.

 

As of the end of the period covered by this report, we conducted an evaluation under the supervision and with the participation of our chief executive officer and principal accounting officer of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange Act).

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be presented or detected on a timely basis.

 

Based on management’s assessment, we have concluded that, as of March 31, 2021, our disclosure controls and procedures were not effective in timely alerting management to the material information relating to us required to be included in our annual and interim filings with the SEC.

 

Our chief executive officer and principal financial officer have concluded that our disclosure controls and procedures had the following material weaknesses:

 

● We were unable to maintain any segregation of duties within our financial operations due to our reliance on limited personnel in the finance function.  While this control deficiency did not result in any audit adjustments to our 2020 interim or annual financial statements, it could have resulted in a material misstatement that might have been prevented or detected by a segregation of duties;

 

● We lack sufficient resources to perform the internal audit function and does not have an Audit Committee;

 

● Documentation of all proper accounting procedures is not yet complete; and

 

● We have no formal control process related to the identification and approval of related party transactions.

 

These weaknesses were identified in our Annual Report on Form 10-K for the year ended December 31, 2020. These weaknesses have existed since our inception on June 28, 2010 and, as of March 31, 2021, have not been remedied.

 

To the extent reasonably possible given our limited financial and personnel resources, we intend to take measures to cure the aforementioned material weaknesses, including, but not limited to, the following:

 

● Consider the engagement of consultants to assist in ensuring that accounting policies and procedures are consistent across the organization and that we have adequate control over financial statement disclosures;

 

● Hire additional qualified financial personnel, including a Chief Financial Officer, on a full-time basis;

 

● Expand our board of directors to include additional independent individuals willing to perform directorial functions; and

 

● Increase our workforce in preparation for commencing revenue producing operations.

 

Since the recited remedial actions will require that we hire or engage additional personnel, these material weaknesses may not be overcome in the near-term due to our limited financial resources.  Until such remedial actions can be realized, we will continue to rely on the limited advice of outside professionals and consultants.

  

Changes in Controls and Procedures

 

There have been no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

11

 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We are not currently a party to any lawsuit or proceeding which, in the opinion of management, is likely to have a material adverse effect on us or our business.

  

ITEM 1A. RISK FACTORS

 

Not applicable for smaller reporting companies.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None 

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

ITEM 6. EXHIBITS

 

Exhibit
Number 		  Description
31.1*   Rule 13a-14(a) Certification of the Chief Executive and Financial Officer
     
32.1*   Section 1350 Certification of Chief Executive and Financial Officer
     
101.INS*   XBRL INSTANCE DOCUMENT
     
101.SCH* XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
     
101.CAL*   XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
     
101.DEF*   XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
     
101.LAB*   XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
     
101.PRE*   XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

 

* Filed along with this document

 

12

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  Tengjun Biotechnology Corp.
  (Registrant)
     
Date: April 16, 2021 By: /s/ Qiuping Lu
    Qiuping Lu
    Chief Executive Officer (Principal Executive Officer), Chief Financial Officer (Principal Financial and Accounting officer), President

 

 

13 

 

 

 

Tengjun Biotechnology (CE) (USOTC:TJBH)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Tengjun Biotechnology (CE) 차트를 더 보려면 여기를 클릭.
Tengjun Biotechnology (CE) (USOTC:TJBH)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Tengjun Biotechnology (CE) 차트를 더 보려면 여기를 클릭.